Brazil's National Health Surveillance Agency (Anvisa) has approved the final administrative step before the formal registration of the single-dose dengue vaccine developed by the São Paulo-based Butantan Institute for people aged 12 to 59, which protects against all four virus serotypes. Read full article
Comments
Disclaimer & comment rulesNo comments for this story
Please log in or register (it’s free!) to comment. Login with Facebook